Inactive Instrument

Opko Health Share Price Nasdaq

Equities

Healthcare Facilities & Services

Sales 2024 * 715M 56.66B Sales 2025 * 754M 59.74B Capitalization 910M 72.06B
Net income 2024 * -265M -21B Net income 2025 * -195M -15.45B EV / Sales 2024 * 1.27 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.21 x
P/E ratio 2024 *
-3.5 x
P/E ratio 2025 *
-4.83 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 45.64%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 87 26/03/07
Director of Finance/CFO 46 28/02/07
President 72 08/05/22
Members of the board TitleAgeSince
Chief Executive Officer 87 26/03/07
Director/Board Member 77 17/12/20
Director/Board Member 68 31/12/07
More insiders
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
Related indices
More about the company